Summary
The dramatic success of two COVID-19 vaccines in clinical trials last month marked a triumph for a previously unproven medical technology. The vaccines, one of which was authorized for emergency use by the U.S. Food and Drug Administration last week, rely on the genetic instruction known as messenger RNA (mRNA). It prompts cells to make a SARS-CoV-2 protein that trains the immune system to recognize the virus. But long before the pandemic, mRNA tantalized pharma, promising a simple and flexible way to deliver both vaccines and drugs. Now, the vaccine wins have created new enthusiasm around the concept. But mRNA medicines—especially those that replace beneficial proteins for chronic disease—have a tougher road to the clinic than vaccines.
"work" - Google News
December 18, 2020 at 01:50AM
https://ift.tt/34mYWy2
mRNA's next challenge: Will it work as a drug? - Science
"work" - Google News
https://ift.tt/3bUEaYA
Bagikan Berita Ini
0 Response to "mRNA's next challenge: Will it work as a drug? - Science"
Post a Comment